NCT03449264

Brief Summary

The BCB is a tool:

  • for research in analytical and public health epidemiology, biological research and for the development of data useful for clinical research and therapeutic trials;
  • to help scientists understand and explain phenomena ranging from the interaction of molecules to the whole metabolism of the organism in normal and pathological situations;
  • to identify potential strategies for prevention, diagnosis, management and analysis of cancer subtypes. The creation of a broad clinical and biological prospective base dedicated to different types of cancer is essential for the development of such projects.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,000

participants targeted

Target at P75+ for not_applicable

Timeline
140mo left

Started Jul 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress43%
Jul 2017Nov 2037

Study Start

First participant enrolled

July 27, 2017

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 29, 2017

Completed
6 months until next milestone

First Posted

Study publicly available on registry

February 28, 2018

Completed
9.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2027

Expected
10 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2037

Last Updated

February 12, 2025

Status Verified

February 1, 2025

Enrollment Period

10.3 years

First QC Date

August 29, 2017

Last Update Submit

February 11, 2025

Conditions

Digestive CancerGynecologic CancerBreast CancerSarcoma

Outcome Measures

Primary Outcomes (1)

  • Proportion of patients who consent to participate in the study

    the proportion of patients who consent to participate in the study among the screened patients

    through study completion, an average of 1 year

Other Outcomes (1)

  • Quality of life assessment at baseline for all participants in the study

    through study completion, an average of 1 year

Study Arms (1)

Biological collection

EXPERIMENTAL

samples of different natures: * Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery. * Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out. In parallel to this biological collection, standardized clinical data will be entered into a database

Biological: biological collection

Interventions

biological collectionBIOLOGICAL

* Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery. * Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.

Biological collection

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age\> at 18 years old,
  • Patient with invasive or in situ tumor pathology (proven or suspected) any stage confounded,
  • Patient in ICM at diagnosis
  • a digestive cancer (esophagus, stomach, pancreas, colon, rectum, anal canal) or
  • gynecological cancer (ovary, endometrium, cervix) or
  • breast cancer or
  • sarcoma.
  • Naïve patient of any treatment for the present cancer,
  • Patient requiring treatment involving at least one (or more) tumor surgery (s)
  • Patient who has accepted supplementary blood samples,
  • Patient having given his informed, written and express consent.

You may not qualify if:

  • Patient not affiliated to a social protection scheme,
  • Patient whose regular follow-up is a priori impossible for psychological, familial, social or geographical reasons,
  • Pregnant and / or nursing women,
  • Subject under tutelage, curatorship or safeguard of justice,
  • Patient in an emergency situation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut regional du Cancer - Val d Aurelle

Montpellier, 34298, France

RECRUITING

MeSH Terms

Conditions

Gastrointestinal NeoplasmsBreast NeoplasmsSarcoma

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesNeoplasms, Connective and Soft TissueNeoplasms by Histologic Type

Study Officials

  • jean pierre Bleuse

    Institut régional du Cancer de Montpellier

    STUDY CHAIR

Central Study Contacts

david azria

CONTACT

+33467613102david.azria@icm.unicancer.fr

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 29, 2017

First Posted

February 28, 2018

Study Start

July 27, 2017

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

November 1, 2037

Last Updated

February 12, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)